The positive CKD sub-analysis strengthens the NDA package ahead of the December 22, 2026 PDUFA date. Traders should monitor for any FDA advisory committee meeting announcements and potential partnership or licensing interest. The stock may see continued momentum as the PDUFA approaches.
Price Chart
Executive Summary
Mineralys Therapeutics presented positive post-hoc data from the Phase 3 Launch-HTN trial at ESH 2026, showing lorundrostat achieved comparable blood pressure reductions in CKD and non-CKD patients and a significant 52.2% placebo-adjusted reduction in albuminuria. The NDA is under FDA review with a PDUFA date of December 22, 2026, making this a key pipeline catalyst for a mid-cap biotech.
Key Facts
- Post-hoc analysis of Phase 3 Launch-HTN trial showed placebo-adjusted SBP reductions of 9.6 mmHg in CKD patients (p=0.0022) and 12.2 mmHg in non-CKD patients (p<0.0001) at week 12.
- In 84 CKD patients with baseline albuminuria, lorundrostat achieved a 52.2% placebo-adjusted reduction in UACR at 12 weeks (p<0.0001).
- Lorundrostat had a favorable safety profile with low confirmed hyperkalemia rates of 2.4% in CKD and 0% in non-CKD patients.
- NDA is under FDA review with a PDUFA target date of December 22, 2026.
- Lorundrostat is a highly selective aldosterone synthase inhibitor with 374-fold selectivity over cortisol synthase.
Financial Impact
Positive clinical data supports NDA approval prospects for lorundrostat, which targets a large market (uncontrolled/resistant hypertension and CKD). Market cap is $2.6B; approval could significantly expand addressable market.
Risk Factors
- FDA may issue a Complete Response Letter (CRL) on safety/efficacy grounds, which would be bearish (expected CAR -5% to -8%).
- CRL on CMC grounds would be less severe but still negative (expected CAR -2% to -5%).
- Competition from other aldosterone synthase inhibitors or existing hypertension therapies could limit commercial uptake.
- Clinical data is post-hoc analysis; FDA may require additional trials for CKD-specific label expansion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303889 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | 3 | $26.09 $28.20 | ▲ +8.09% | ▲ +9.83% | $23.56 (−9.70%) |
Jul 23, 2026 10w ago | Insider Cluster | $26.71 $25.65 | ▼ −3.97% | ▼ −7.59% | $23.56 (−11.79%) |
Jul 21, 2026 10w ago | Insider Cluster | $27.52 $26.61 | ▼ −3.31% | ▼ −5.87% | $23.56 (−14.39%) |
Jul 16, 2026 11w ago | Insider Cluster | $27.08 $26.09 | ▼ −3.66% | ▼ −7.27% | $23.56 (−13.00%) |
Jun 30, 2026 13w ago | 144 | $26.89 $26.35 | ▼ −2.01% | ▲ +0.18% | $23.56 (−12.38%) |
Jun 29, 2026 13w ago | 144 | $26.88 $26.71 | ▼ −0.63% | ▼ −0.35% | $23.56 (−12.35%) |
Jun 18, 2026 15w ago | Insider Cluster | $24.63 $27.08 | ▲ +9.95% | ▲ +9.41% | $23.56 (−4.34%) |
Jun 17, 2026 15w ago | 144 | $24.63 $27.08 | ▲ +9.95% | ▲ +9.41% | $23.56 (−4.34%) |
Jun 11, 2026 16w ago | Institutional Cluster | $23.94 $28.96 | ▲ +20.97% | ▲ +19.08% | $23.56 (−1.59%) |
Jun 3, 2026 17w ago | 8-K | $25.06 $27.69 | ▲ +10.49% | ▲ +11.49% | $23.56 (−5.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access